|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-06S1
|
$74,858
|
$749
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-06
|
$1,560,000
|
$15,600
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Validating the prognostic value of EGFR768 in neuroblastoma
|
1R21CA187554-01
|
$169,711
|
$169,711
|
CHAN, EDWARD
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S1
|
$74,856
|
$1,497
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S2
|
$122,401
|
$2,448
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S3
|
$150,000
|
$3,000
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-40
|
$4,421,130
|
$88,423
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S1
|
$75,000
|
$9,000
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S2
|
$4,154
|
$498
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S3
|
$12,487
|
$1,498
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S4
|
$126,993
|
$15,239
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-39
|
$6,071,261
|
$728,551
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Uncovering the anti-apoptotic mechanism of mutated ALK in neuroblastoma
|
1F32CA183566-01A1
|
$51,530
|
$51,530
|
MOORE, NATHAN
|
DANA-FARBER CANCER INST
|
|
Tumor-produced TNF alpha as an inducer of immune resistance and tumor survival
|
5R01CA136663-05
|
$320,189
|
$320,189
|
LEVITSKAIA, ELENA
|
JOHNS HOPKINS UNIVERSITY
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$358,240
|
$32,242
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy
|
5R01CA166105-03
|
$328,681
|
$197,209
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-07
|
$562,701
|
$562,701
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
3R01CA148688-04S1
|
$106,528
|
$106,528
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-04
|
$352,231
|
$352,231
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
1R01CA174808-01A1
|
$326,348
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
2R01CA140198-06
|
$404,266
|
$404,266
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Neuroblastoma with armed T cells
|
1R01CA182526-01A1
|
$802,464
|
$802,464
|
LUM, LAWRENCE
|
WAYNE STATE UNIVERSITY
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
5U01CA168426-03
|
$1,165,605
|
$1,165,605
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
3U24CA114766-08S1
|
$1,510,732
|
$302,146
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
St. Vincent Hospital Regional Cancer Center CCOP
|
3U10CA095968-12S1
|
$139,195
|
$4,176
|
JASLOWSKI, ANTHONY
|
ST. VINCENT HOSPITAL
|
|
Sphingosine-1-Phosphate Pathway Based Therapy for Neuroblastoma
|
5R01CA168903-03
|
$335,040
|
$335,040
|
FERRER, FERNANDO
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
Specialized Cancer Center Support Grant
|
2P30CA023100-28
|
$3,730,476
|
$111,914
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-28S1
|
$75,000
|
$2,250
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-28S2
|
$112,769
|
$3,383
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-28S3
|
$33,334
|
$1,000
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
South Texas Pediatric Minority Based CCOP
|
3U10CA052771-23S1
|
$52,916
|
$2,646
|
LANGEVIN, ANNE-MARIE
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
Role of Trk Receptors in the Development and Function of Non-neuronal Structures
|
ZIA BC 010391
|
$524,012
|
$52,401
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$524,012
|
$104,802
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-07
|
$243,655
|
$60,914
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Regulation of Differentiation of Pediatric Embryonal Tumors- Neuroblastoma
|
ZIA BC 010788
|
$577,062
|
$346,237
|
Thiele, Carol
|
CCR (NCI)
|
|
Regional Oncology Research Center
|
3P30CA006973-51S1
|
$75,000
|
$750
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-51S3
|
$324,000
|
$3,240
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-51
|
$6,785,409
|
$67,854
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Quantitative SPECT for Targeted Radionuclide Therapy
|
5R01CA109234-09
|
$403,527
|
$100,882
|
FREY, ERIC
|
JOHNS HOPKINS UNIVERSITY
|
|
Quantitative and Spatial Optimization for Designing Cancer Therapeutics
|
5F32CA168274-03
|
$56,978
|
$28,489
|
ROBINSON-MOSHER, AVRAM
|
HARVARD MEDICAL SCHOOL
|
|
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy
|
5R01CA154561-04
|
$409,896
|
$409,896
|
SEO, YOUNGHO
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Predicting toxicity and success of anti-GD2 immunotherapy of neuroblastoma
|
5R01CA164132-03
|
$311,976
|
$311,976
|
YU, ALICE
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-07
|
$232,069
|
$232,069
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
|
5R01CA168699-02
|
$275,539
|
$275,539
|
KANG, MIN
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
Pharmacogenetics in children with high-risk neuroblastoma
|
5R03CA178104-02
|
$75,598
|
$75,598
|
MCCUNE, JEANNINE
|
UNIVERSITY OF WASHINGTON
|
|
Perinatal, Familial, and Neighborhood Risk Factors for Childhood Cancer
|
5R03CA171017-02
|
$48,190
|
$4,819
|
CRUMP, CASEY
|
LUND UNIVERSITY
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,301,947
|
$165,097
|
Merchant, Melinda
|
CCR (NCI)
|
|
Pediatric Cancer, Family Conflict and Child Adjustment
|
5R01CA134794-05
|
$281,660
|
$70,415
|
KATZ, LYNN
|
UNIVERSITY OF WASHINGTON
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
ZIA BC 010789
|
$310,725
|
$279,653
|
Thiele, Carol
|
CCR (NCI)
|
|
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma
|
5K99CA178189-02
|
$122,683
|
$122,683
|
ZHU, SHIZHEN
|
MAYO CLINIC ROCHESTER
|
Total relevant funding to Neuroblastoma for this search: $23,581,708
|